Cytek Biosciences (CTKB) Stock News, Apr-Oct 2025

Cytek Biosciences (Nasdaq: CTKB) announced it has relocated its European headquarters to a new facility in Amsterdam's Life Sciences District effective Oct 15, 2025. The site expands Cytek's European footprint by more than 40% and houses offices, an enlarged warehouse, and a dedicated customer service and training center with a fully functional lab for hands-on training on Cytek's Full Spectrum Profiling™ (FSP®) technology.

The company cited strong reagent-business performance as a key driver and has transitioned warehouse operations in-house to improve quality control, operational agility, and turnaround times across EMEA.

Cytek Biosciences (NASDAQ:CTKB), a leader in spectral flow cytometry, will showcase its advanced cell analysis solutions at two major clinical conferences: ESCCA 2025 (September 17-20 in Montpellier, France) and ICCS 2025 (September 28-30 in Philadelphia).

The company's Full Spectrum Profiling™ (FSP®) technology has gained significant traction, with over 2,800 peer-reviewed publications citing its use. The technology enables profiling of more than 40 markers in a single tube, enhancing efficiency and reducing analysis time.

At both conferences, experts will present workshops on integrating spectral flow cytometry with machine learning for improved leukemia and lymphoma diagnosis, demonstrating the technology's practical applications in clinical settings.

Cytek Biosciences (Nasdaq: CTKB), a leading cell analysis solutions company, has announced its participation in three upcoming investor conferences in August and September 2025.

The company will participate in: the UBS Precision Medicine Summit with a panel discussion on August 14, the Wells Fargo Healthcare Conference with 1x1 investor meetings on September 4, and the Morgan Stanley Global Healthcare Conference with a fireside chat on September 10. Live and archived webcasts for the UBS and Morgan Stanley events will be available on the company's investor relations website.

Cytek Biosciences (Nasdaq: CTKB) reported Q2 2025 financial results, with total revenue of $45.6 million, marking a 2% decrease from Q2 2024. The company expanded its installed base to 3,295 instruments, adding 146 units in Q2 2025. Notable highlights include the launch of the Cytek Aurora™ Evo system and 16% growth in recurring revenue, which now accounts for 32% of trailing 12-month revenue.

The company reported a net loss of $5.6 million and Adjusted EBITDA of $1.3 million. Cash position remained strong at $262.0 million. Cytek repurchased $4.5 million of common stock during Q2 and narrowed its 2025 revenue guidance to $196-205 million, projecting -2% to +2% growth over 2024.

Cytek Biosciences (Nasdaq: CTKB) has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after market close. The company will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET on the same day, where management will discuss quarterly results, business developments, and future outlook. Investors can access the live webcast through the company's investor relations website at investors.cytekbio.com.

Cytek Biosciences (NASDAQ: CTKB) has launched the Cytek Aurora™ Evo system, an enhanced version of their flagship full spectrum flow cytometer. The new system builds on the success of the original Aurora, which has been cited in over 2,600 peer-reviewed publications. Key improvements include 2x faster sample acquisition, automated maintenance, and built-in small particle detection capabilities. The Aurora Evo features enhanced throughput (up to 200 µL/min), instrument standardization for consistent data across labs, and integrated automation with plate loader support. The system maintains Cytek's Full Spectrum Profiling™ (FSP®) technology, allowing researchers to conduct large multicolor experiments while analyzing both small particles and large cells. This launch reinforces Cytek's position in advancing cell analysis technology for immunology, oncology, and therapeutic research.

Cytek Biosciences (NASDAQ: CTKB), a cell analysis solutions company, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL. The company's management will engage in a fireside chat on June 11th at 11:40 a.m. PT / 2:40 p.m. ET. Investors and interested parties can access both live and archived webcasts of the presentation through the company's investor relations website at investors.cytekbio.com.

Cytek Biosciences (NASDAQ: CTKB) reported Q1 2025 financial results with total revenue of $41.5 million, marking a 7.6% decrease from Q1 2024. The company expanded its installed base to 3,149 instruments, adding 115 units in Q1. Key developments include commencing operations in Singapore for low-cost manufacturing and launching the Cytek Muse® Micro instrument. Financial highlights show a gross profit of $20.2 million (49% margin) and a net loss of $11.4 million. The company maintains a strong balance sheet with $265.6 million in cash and marketable securities. During Q1, Cytek repurchased $10.6 million of common stock. The company revised its 2025 revenue guidance to $196-210 million, projecting -2% to 5% growth over 2024.

Cytek Biosciences (Nasdaq: CTKB) is showcasing its patented Full Spectrum Profiling™ (FSP®) technology at two major industry events: CYTO 2025 and IMMUNOLOGY2025. The company will conduct demonstrations, educational workshops, and tutorials at both conferences.

At IMMUNOLOGY2025 (May 3-7 in Honolulu), Dr. Eleanor Kincaid will host a workshop on mouse immune response characterization. The company will display its complete cell analysis solutions, including instruments, reagents, Cytek® Cloud, software, and services at Booth 801.

As a Platinum sponsor at CYTO 2025 (May 31-June 4 in Denver), Cytek will showcase its technology at Booth 401. CEO Wenbin Jiang emphasizes the company's commitment to making spectral flow cytometry more accessible, focusing on high-growth areas like immunology, oncology, and cell therapy.

The company's FSP technology aims to streamline workflows, accelerate discoveries, and enhance efficiency in both research and clinical studies.